Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell LymphomaFrederick L. Locke, Jason R. Westin, David B. Miklos et al.|New England Journal of Medicine|2021Cited by 1.6k
Survival with Axicabtagene Ciloleucel in Large B-Cell LymphomaJason R. Westin, Frederick L. Locke, Olalekan O. Oluwole et al.|New England Journal of Medicine|2023Cited by 437
NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)Sairah Ahmed, Joseph P. McGuirk, John F. DiPersio et al.|Blood|2024Cited by 3
NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)Sairah Ahmed, Joseph P. McGuirk, Christie Fanton et al.|Transplantation and Cellular Therapy|2025Cited by 3